FLASH: Stallergenes secures €50M credit

Stallergenes Greer plc a biopharmaceutical company specializing in treatments for respiratory allergies, today announced it secured a 50 million Euros revolving credit.

The company said that the credit- subject to customary closing conditions – will take the form of a revolving credit line composed of one single tranche, provided by UBS Switzerland AG.

The facility will be used for general corporate purposes.

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s